Inflammation in gout: Mechanisms and therapeutic targets

Nature Reviews Rheumatology

Volumn 13, Issue 11, 2017, Pages 639-647

  So, Alexander K ^a   Martinon, Fabio ^b  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b UNIVERSITY OF LAUSANNE   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CRYOPYRIN; INFLAMMASOME; INTERLEUKIN 1BETA; INTERLEUKIN 1BETA CONVERTING ENZYME INHIBITOR; INTERLEUKIN 8; URATE; URIC ACID; CYTOKINE;

ARTHRITIS; CATALYSIS; CELL INTERACTION; CRYSTAL; CYTOKINE PRODUCTION; DISEASE COURSE; ENVIRONMENTAL FACTOR; GOUT; HEREDITY; HUMAN; INFLAMMATION; INNATE IMMUNITY; MICROBIOME; NONHUMAN; PRIORITY JOURNAL; PROTEIN ASSEMBLY; PROTEIN FUNCTION; PROTEIN PROCESSING; REVIEW; SIGNAL TRANSDUCTION; SOLUBILITY; THERAPY EFFECT; URIC ACID BLOOD LEVEL; IMMUNOLOGY; IMMUNOSUPPRESSIVE TREATMENT; MACROPHAGE; METABOLISM; NEUTROPHIL; PROCEDURES;

CYTOKINES; GOUT; HUMANS; IMMUNITY, INNATE; IMMUNOSUPPRESSION; INFLAMMASOMES; INFLAMMATION; MACROPHAGES; NEUTROPHILS;

EID: 85032644870     PISSN: 17594790     EISSN: 17594804     Source Type: Journal    
DOI: 10.1038/nrrheum.2017.155     Document Type: Review

References (79)

1. Kuo, C. F., Grainge, M. J., Zhang, W. & Doherty, M. Global epidemiology of gout: Prevalence, incidence and risk factors. Nat. Rev. Rheumatol. 11, 649-662 (2015).
2. Dalbeth, N., Merriman, T. R. & Stamp, L. K. Gout. Lancet 388, 2039-2052 (2016).
3. McGonagle, D. & McDermott, M. F. A proposed classification of the immunological diseases. PLoS Med. 3, e297 (2006).
4. Martinon, F. & Glimcher, L. H. Gout: new insights into an old disease. J. Clin. Invest. 116, 2073-2075 (2006).
5. Broz, P. & Dixit, V. M. Inflammasomes: Mechanism of assembly, regulation and signalling. Nat. Rev. Immunol. 16, 407-420 (2016).
6. Martinon, F., Burns, K. & Tschopp, J. The inflammasome: A molecular platform triggering activation of inflammatory caspases and processing of pro-IL-β. Mol. Cell 10, 417-426 (2002).
7. Cai, X. et al. Prion-like polymerization underlies signal transduction in antiviral immune defense and inflammasome activation. Cell 156, 1207-1222 (2014).
8. Chen, C. J. et al. MyD88-dependent IL-1 receptor signaling is essential for gouty inflammation stimulated by monosodium urate crystals. J. Clin. Invest. 116, 2262-2271 (2006).
9. Aglietti, R. A. & Dueber, E. C. Recent insights into the molecular mechanisms underlying pyroptosis and gasdermin family functions. Trends Immunol. 38, 261-271 (2017).
10. Abhishek, A. et al. In vivo detection of monosodium urate crystal deposits by Raman spectroscopy - a pilot study. Rheumatology (Oxford) 55, 379-380 (2016).
11. Kayagaki, N. et al. Caspase-11 cleaves gasdermin D for non-canonical inflammasome signalling. Nature 526, 666-671 (2015).
12. Mulay, S. R. et al. Cytotoxicity of crystals involves RIPK3-MLKL-mediated necroptosis. Nat. Commun. 7, 10274 (2016).
13. Vince, J. E. et al. Inhibitor of apoptosis proteins limit RIP3 kinase-dependent interleukin-1 activation. Immunity 36, 215-227 (2012).
14. Liu-Bryan, R., Scott, P., Sydlaske, A., Rose, D. M. & Terkeltaub, R. Innate immunity conferred by Toll-like receptors 2 and 4 and myeloid differentiation factor 88 expression is pivotal to monosodium urate monohydrate crystal-induced inflammation. Arthritis Rheum. 52, 2936-2946 (2005).
15. Martinon, F., Petrilli, V., Mayor, A., Tardivel, A. & Tschopp, J. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 440, 237-241 (2006).
16. Burns, K., Martinon, F. & Tschopp, J. New insights into the mechanism of IL-1β maturation. Curr. Opin. Immunol. 15, 26-30 (2003).
17. Holzinger, D. et al. Myeloid-related proteins 8 and 14 contribute to monosodium urate monohydrate crystal-induced inflammation in gout. Arthritis Rheumatol. 66, 1327-1339 (2014).
18. Joosten, L. A. et al. Engagement of fatty acids with Toll-like receptor 2 drives interleukin-1beta production via the ASC/caspase 1 pathway in monosodium urate monohydrate crystal-induced gouty arthritis. Arthritis Rheum. 62, 3237-3248 (2010).
19. Joosten, L. A., Abdollahi-Roodsaz, S., Dinarello, C. A., O'Neill, L. & Netea, M. G. Toll-like receptors and chronic inflammation in rheumatic diseases: new developments. Nat. Rev. Rheumatol. 12, 344-357 (2016).
20. An, L. L. et al. Complement C5a potentiates uric acid crystal-induced IL-1β production. Eur. J. Immunol. 44, 3669-3679 (2014).
21. Khameneh, H. J. et al. C5a regulates IL-1β production and leukocyte recruitment in a murine model of monosodium urate crystal-induced peritonitis. Front. Pharmacol. 8, 10 (2017).
22. Petrilli, V. et al. Activation of the NALP3 inflammasome is triggered by low intracellular potassium concentration. Cell Death Differ. 14, 1583-1589 (2007).
23. Yaron, J. R. et al. K+ regulates Ca2+ to drive inflammasome signaling: Dynamic visualization of ion flux in live cells. Cell Death Dis. 6, e1954 (2015).
24. Amaral, F. A. et al. NLRP3 inflammasome-mediated neutrophil recruitment and hypernociception depend on leukotriene B4 in a murine model of gout. Arthritis Rheum. 64, 474-484 (2012).
25. He, Y., Zeng, M. Y., Yang, D., Motro, B. & Nunez, G. NEK7 is an essential mediator of NLRP3 activation downstream of potassium efflux. Nature 530, 354-357 (2016).
26. Schmid-Burgk, J. L. et al. A genome-wide CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) screen identifies NEK7 as an essential component of NLRP3 inflammasome activation. J. Biol. Chem. 291, 103-109 (2016).
27. Shi, H. et al. NLRP3 activation and mitosis are mutually exclusive events coordinated by NEK7, a new inflammasome component. Nat. Immunol. 17, 250-258 (2016).
28. Dinarello, C. A. Immunological and inflammatory functions of the interleukin-1 family. Annu. Rev. Immunol. 27, 519-550 (2009).
29. Schlesinger, N. & Thiele, R. G. The pathogenesis of bone erosions in gouty arthritis. Ann. Rheum. Dis. 69, 1907-1912 (2010).
30. Dinarello, C. A. Infection, fever, and exogenous and endogenous pyrogens: Some concepts have changed. J. Endotoxin Res. 10, 201-222 (2004).
31. Netea, M. G., van de Veerdonk, F. L., van der Meer, J. W., Dinarello, C. A. & Joosten, L. A. Inflammasome-independent regulation of IL-1-family cytokines. Annu. Rev. Immunol. 33, 49-77 (2015).
32. Sugawara, S. et al. Neutrophil proteinase 3-mediated induction of bioactive IL-18 secretion by human oral epithelial cells. J. Immunol. 167, 6568-6575 (2001).
33. Mizutani, H., Schechter, N., Lazarus, G., Black, R. A. & Kupper, T. S. Rapid and specific conversion of precursor interleukin 1 beta (IL-1β) to an active IL-1 species by human mast cell chymase. J. Exp. Med. 174, 821-825 (1991).
34. Echtermeyer, F. et al. Syndecan-4 regulates ADAMTS-5 activation and cartilage breakdown in osteoarthritis. Nat. Med. 15, 1072-1076 (2009).
35. Irmler, M. et al. Granzyme A is an interleukin 1β-converting enzyme. J. Exp. Med. 181, 1917-1922 (1995).
36. Pazar, B. et al. Basic calcium phosphate crystals induce monocyte/macrophage IL-1β secretion through the NLRP3 inflammasome in vitro. J. Immunol. 186, 2495-2502 (2011).
37. Dumusc, A. & So, A. Interleukin-1 as a therapeutic target in gout. Curr. Opin. Rheumatol. 27, 156-163 (2015).
38. Kienhorst, L. B. et al. Gout is a chronic inflammatory disease in which high levels of interleukin-8 (CXCL8), myeloid-related protein 8/myeloid-related protein 14 complex, and an altered proteome are associated with diabetes mellitus and cardiovascular disease. Arthritis Rheumatol. 67, 3303-3313 (2015).
39. Crisan, T. O. et al. Soluble uric acid primes TLR-induced proinflammatory cytokine production by human primary cells via inhibition of IL-1Ra. Ann. Rheum. Dis. 75, 755-762 (2016).
40. Choi, H. K., Atkinson, K., Karlson, E. W., Willett, W. & Curhan, G. Purine-rich foods, dairy and protein intake, and the risk of gout in men. N. Engl. J. Med. 350, 1093-1103 (2004).
41. Zhang, Y. et al. Purine-rich foods intake and recurrent gout attacks. Ann. Rheum. Dis. 71, 1448-1453 (2012).
42. Vieira, A. T. et al. A role for gut microbiota and the metabolite-sensing receptor GPR43 in a murine model of gout. Arthritis Rheumatol. 67, 1646-1656 (2015).
43. Vieira, A. T. et al. Dietary fiber and the short-chain fatty acid acetate promote resolution of neutrophilic inflammation in a model of gout in mice. J. Leukocyte Biol. 101, 275-284 (2017).
44. Guo, Z. et al. Intestinal microbiota distinguish gout patients from healthy humans. Sci. Rep. 6, 20602 (2016).
45. Ragab, G., Elshahaly, M. & Bardin, T. Gout: An old disease in new perspective - a review. J. Adv. Res. 8, 495-511 (2017).
46. Abhishek, A., Valdes, A. M. & Doherty, M. Low omega-3 fatty acid levels associate with frequent gout attacks: A case control study. Ann. Rheum. Dis. 75, 784-785 (2016).
47. Yan, Y. et al. Omega-3 fatty acids prevent inflammation and metabolic disorder through inhibition of NLRP3 inflammasome activation. Immunity 38, 1154-1163 (2013).
48. Merriman, T. R. An update on the genetic architecture of hyperuricemia and gout. Arthritis Res. Ther. 17, 98 (2015).
49. McKinney, C. et al. Multiplicative interaction of functional inflammasome genetic variants in determining the risk of gout. Arthritis Res. Ther. 17, 288 (2015).
50. Lee, Y. H. & Bae, S. C. Association between functional NLRP3 polymorphisms and susceptibility to autoimmune and inflammatory diseases: A meta-analysis. Lupus 25, 1558-1566 (2016).
51. Qing, Y. F. et al. Association of TLR4 gene rs2149356 polymorphism with primary gouty arthritis in a case-control study. PLoS ONE 8, e64845 (2013).
52. Rasheed, H. et al. The Toll-like receptor 4 (TLR4) variant rs2149356 and risk of gout in European and Polynesian sample sets. PLoS ONE 11, e0147939 (2016).
53. Chang, W. C. et al. Genetic variants of PPAR-γ coactivator 1B augment NLRP3-mediated inflammation in gouty arthritis. Rheumatology (Oxford) 56, 457-466 (2017).
54. Popa-Nita, O. & Naccache, P. H. Crystal-induced neutrophil activation. Immunol. Cell Biol. 88, 32-40 (2010).
55. Schauer, C. et al. Aggregated neutrophil extracellular traps limit inflammation by degrading cytokines and chemokines. Nat. Med. 20, 511-517 (2014).
56. Desai, J. et al. PMA and crystal-induced neutrophil extracellular trap formation involves RIPK1-RIPK3- MLKL signaling. Eur. J. Immunol. 46, 223-229 (2016).
57. Carling, D. AMPK signalling in health and disease. Curr. Opin. Cell Biol. 45, 31-37 (2017).
58. Wang, Y., Viollet, B., Terkeltaub, R. & Liu-Bryan, R. AMP-activated protein kinase suppresses urate crystal-induced inflammation and transduces colchicine effects in macrophages. Ann. Rheum. Dis. 75, 286-294 (2016).
59. Liote, F. et al. Inhibition and prevention of monosodium urate monohydrate crystal-induced acute inflammation in vivo by transforming growth factor β1. Arthritis Rheum. 39, 1192-1198 (1996).
60. Chen, Y. H. et al. Spontaneous resolution of acute gouty arthritis is associated with rapid induction of the anti-inflammatory factors TGFβ1, IL-10 and soluble TNF receptors and the intracellular cytokine negative regulators CIS and SOCS3. Ann. Rheum. Dis. 70, 1655-1663 (2011).
61. Galvao, I. et al. Annexin A1 promotes timely resolution of inflammation in murine gout. Eur. J. Immunol. 47, 585-596 (2017).
62. Ter Horst, R. et al. Host and environmental factors influencing individual human cytokine responses. Cell 167, 1111-1124.e13 (2016).
63. Joosten, L. A. et al. Alpha-1-anti-trypsin-Fc fusion protein ameliorates gouty arthritis by reducing release and extracellular processing of IL-1β and by the induction of endogenous IL-1Ra. Ann. Rheum. Dis. 75, 1219-1227 (2016).
64. Elliot, A. J., Cross, K. W. & Fleming, D. M. Seasonality and trends in the incidence and prevalence of gout in England and Wales 1994-2007. Ann. Rheum. Dis. 68, 1728-1733 (2009).
65. Misawa, T. et al. Microtubule-driven spatial arrangement of mitochondria promotes activation of the NLRP3 inflammasome. Nat. Immunol. 14, 454-460 (2013).
66. Youm, Y. H. et al. The ketone metabolite β-hydroxybutyrate blocks NLRP3 inflammasome-mediated inflammatory disease. Nat. Med. 21, 263-269 (2015).
67. Goldberg, E. L. et al. β-Hydroxybutyrate deactivates neutrophil NLRP3 inflammasome to relieve gout flares. Cell Rep. 18, 2077-2087 (2017).
68. Jhang, J. J., Lu, C. C. & Yen, G. C. Epigallocatechin gallate inhibits urate crystals-induced peritoneal inflammation in C57BL/6 mice. Mol. Nutr. Food Res. 60, 2297-2303 (2016).
69. Dhanasekar, C., Kalaiselvan, S. & Rasool, M. Morin, a bioflavonoid suppresses monosodium urate crystal-induced inflammatory immune response in RAW 264.7 macrophages through the inhibition of inflammatory mediators, intracellular ROS levels and NF-κB activation. PLoS ONE 10, e0145093 (2015).
70. Kim, S. K., Choe, J. Y. & Park, K. Y. Rebamipide suppresses monosodium urate crystal-induced interleukin-1β production through regulation of oxidative stress and caspase-1 in THP-1 cells. Inflammation 39, 473-482 (2016).
71. Ives, A. et al. Xanthine oxidoreductase regulates macrophage IL-1β secretion upon NLRP3 inflammasome activation. Nat. Commun. 6, 6555 (2015).
72. Perregaux, D. G. et al. Identification and characterization of a novel class of interleukin-1 post-translational processing inhibitors. J. Pharmacol. Exp. Ther. 299, 187-197 (2001).
73. Coll, R. C. et al. A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases. Nat. Med. 21, 248-255 (2015).
74. Primiano, M. J. et al. Efficacy and pharmacology of the NLRP3 inflammasome inhibitor CP-456, 773 (CRID3) in murine models of dermal and pulmonary inflammation. J. Immunol. 197, 2421-2433 (2016).
75. Wannamaker, W. et al. (S)-1-((S)-2-{[1- (4-amino-3-chloro-phenyl)-methanoyl]-amino}- 3, 3-dimethyl-butanoy l)-pyrrolidine-2-carboxylic acid ((2R, 3S)-2-ethoxy-5-oxo-tetrahydro-furan-3-yl)-amide (VX-765), an orally available selective interleukin (IL)- converting enzyme/caspase-1 inhibitor, exhibits potent anti-inflammatory activities by inhibiting the release of IL-1β and IL-18. J. Pharmacol. Exp. Ther. 321, 509-516 (2007).
76. Zhang, Y. & Zheng, Y. Effects and mechanisms of potent caspase-1 inhibitor VX765 treatment on collagen-induced arthritis in mice. Clin. Exp. Rheumatol. 34, 111-118 (2016).
77. Joosten, L. A. et al. Inflammatory arthritis in caspase 1 gene-deficient mice: Contribution of proteinase 3 to caspase 1-independent production of bioactive interleukin-1β. Arthritis Rheum. 60, 3651-3662 (2009).
78. Alten, R. et al. Efficacy of canakinumab on re-treatment in gouty arthritis patients with limited treatment options: 24-week results from β-RELIEVED and β-RELIEVED-II [abstract]. Arthritis Rheum. 63 (Suppl.), S402 (2011).
79. Hornung, V. et al. Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization. Nat. Immunol. 9, 847-856 (2008).